Eli Lilly’s weight loss and diabetes drug tops Keytruda
Digest more
U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled to $3.57 billion in the third quarter. Meanwhile, revenue ...
In parallel with mazisotine’s shelving, Lilly added a phase 1 NaV1.8 inhibitor from its SiteOne Therapeutics acquisition to ...
The Big Pharma mainstay blew away EPS and revenue expectations when it reported Q3 financials, with management raising ...
Eli Lilly stock (NYSE: LLY) is up 7% in a month, warranting investor attention following a key corporate development. Eli ...
The restaurant chain posted a drop in net income and quarterly revenue missed forecasts. Chipotle said economic strains were ...
Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.
Eli Lilly’s stock rallies, as Zepbound sales nearly tripled, leading to record revenue and a raised full-year outlook.
Revenue from Mounjaro, the company’s Type 2 diabetes treatment, came in at $6.5 billion, above analysts’ consensus estimate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback